Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889172 | 0.82 | AKT1 (0.43) | AKR1B1TSHRAKT1CYP2D6 | |
| SCHEMBL3996987 | 0.82 | AKR1B1 (0.63) | AKR1B1HSPA5TSHRCYP2D6HIF1A | |
| SCHEMBL9308692 | 0.81 | TAAR1 (0.47) | AKR1B1HSPA5TSHRCYP2D6HIF1A | |
| SCHEMBL15946705 | 0.78 | ALDH1A1 (0.41) | AKR1B1TSHRAKT1 | |
| SCHEMBL705718 | 0.78 | CTBP2 (0.50) | AKT1TAAR1 | |
| SCHEMBL6922195 | 0.77 | AKR1B1 (0.57) | AKR1B1HSPA5TSHRCYP2D6HIF1A | |
| SCHEMBL28424162 | 0.77 | AKT1 (0.39) | AKR1B1TSHRAKT1HIF1A | |
| SCHEMBL1737314 | 0.76 | AKR1B1 (0.74) | AKR1B1HSPA5TSHRCYP2D6HIF1A | |
| SCHEMBL30451705 | 0.76 | AKR1B1 (0.74) | AKR1B1HSPA5TSHRCYP2D6HIF1A | |
| SCHEMBL72309 | 0.76 | AKR1B1 (1.00) | AKR1B1HSPA5TSHRCYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230721-B2 | Production of a flavour compound in a host cell | AXXENCE AROMATIC GMBH (DE) | 2022-01-25 | — | — | US | disclosed |
| US-20200392544-A1 | Production of a flavour compound in a host cell | AXXENCE HOLDING B.V. (NL) | 2020-12-17 | — | — | US | disclosed |
| EP-3714056-A1 | PRODUCTION OF A FLAVOUR COMPOUND IN A HOST CELL | Axxence Holding B.V. (NL) | 2020-09-30 | — | — | EP | disclosed |
| CN-111566217-A | Production of flavor compounds in host cells | 艾克森斯控股有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-107056687-B | Pyridine group-containing 1, 4-pentadiene-3-ketoxime ester compound, preparation method and application | 贵州大学 | 2020-06-30 | — | — | CN | disclosed |
| EP-3564204-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3045445-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2606021-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-07-31 | — | — | EP | disclosed |
| CN-107056687-A | The ketoxime ester compound of 1,4 pentadiene 3, Preparation method and use containing pyridine groups | 贵州大学 | 2017-08-18 | — | — | CN | disclosed |
| EP-3045445-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | THE UNIVERSITY OF TOKYO (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | ALLIANZ PHARMASCIENCE LTD. (TW) | 2014-12-18 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | PDCD5, IL5, MALT1 | AKR1B1 763/4885HSPA5 3244/4885TSHR 3239/4885 |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | PHOSPHO1, SELENOI, CD2 | AKR1B1 2836/4885HSPA5 3313/4885TSHR 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.